Symeres and Ambagon Partner to Develop Molecular Glue Therapeutics for Colorectal Cancer
Key Insights
Symeres (search) has entered a collaboration with Ambagon Therapeutics (search) to explore molecular glues (search), an emerging class of small molecules that enable protein interactions for colorectal cancer (search) treatment.
The partnership will utilize advanced techniques including surface plasmon resonance and cellular assays to assess molecular glues (search) through mechanistic studies focusing on ternary complex kinetics.
Symeres (search) will contribute synthesis and validation services, including profiling compounds across its 102 cancer cell line panel to support progression toward investigational new drug applications.
Symeres (search) has entered a strategic collaboration with Ambagon Therapeutics (search) to advance molecular glue research targeting colorectal cancer (search), focusing on diseases traditionally considered difficult to treat. The partnership aims to explore molecular glues (search), an emerging class of small molecules that enable or stabilize interactions between proteins (search), potentially expanding therapeutic options for oncology patients.
Novel Therapeutic Approach
Molecular glues (search) represent an emerging therapeutic modality with significant potential to expand the druggable proteome while reducing toxicity compared to conventional inhibitors or activators. This innovative approach addresses one of oncology's most persistent challenges: targeting previously undruggable proteins (search) that have remained beyond the reach of traditional drug development strategies.
The collaboration will leverage Symeres (search)' comprehensive research capabilities to assess Ambagon's molecular glues (search) through sophisticated in vitro assays and mechanistic studies focusing on ternary complex kinetics. The technical approach encompasses multiple analytical methods, including surface plasmon resonance using ResidenceTimer technology, alongside cellular assays designed to analyze the impact on disease-relevant pathways.
Comprehensive Research Platform
The research program will employ advanced methodologies including fluorescence microscopy to examine target protein nuclear translocation inhibition, quantitative polymerase chain reaction (qPCR), and Western blot analysis for downstream pathway activity assessment. Cancer cell viability assays will be utilized to evaluate the therapeutic potential of the molecular glue candidates.
Symeres (search) will contribute to the broader development program through its synthesis and validation services, including profiling compounds across its extensive 102 cancer cell line panel. This comprehensive screening approach is designed to provide early understanding of compound behavior and support progression toward investigational new drug (IND) applications.
Industry Leadership Perspectives
"Targeting previously undruggable proteins (search) remains one of the key challenges in oncology drug discovery," said Jorg Benningshof, managing director of Symeres (search) company Oncolines (search). "By combining Ambagon's molecular glue technology with our translational research capabilities, we aim to generate meaningful insights to accelerate preclinical development across a variety of therapeutic conditions."
Christian Ottmann, co-founder and chief scientific officer of Ambagon Therapeutics (search), emphasized the strategic value of the partnership: "This collaboration enables us to deepen our understanding of how molecular glues (search) can modulate disease-relevant pathways in colorectal cancer (search). Working with Symeres (search) provides access to robust validation platforms that are critical for progressing our pipeline."
Advancing Colorectal Cancer Treatment
The collaboration represents a significant step forward in addressing the unmet medical needs in colorectal cancer (search) treatment. By focusing on molecular glues (search)' unique mechanism of action, the partnership aims to unlock new therapeutic possibilities for patients facing limited treatment options in this challenging disease area.